IMNM logo

Immunome, Inc.


IMNM: Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious disease, including COVID-19. It primarily operates in the U.S. Its current programs comprise Oncology (IMM-ONC-01), SARS-CoV-2 (IMM-BCP-01), and IMM20059 Anti-EPN1.


Show IMNM Financials

Consumer Interest
SEC Filings

Recent trades of IMNM by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by IMNM's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard

Government lobbying spending instances

  • $10,000 Jul 16, 2022 Issue: Health Issues
  • $10,000 Oct 18, 2021 Issue: Health Issues
  • $20,000 Jul 20, 2020 Issue: Health Issues
U.S. Patents

New patents grants

Quiver Logo

No new patents for this ticker

U.S. Patents Dashboard
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of IMNM in WallStreetBets Daily Discussion


Recent insights relating to IMNM

CNBC Recommendations

Recent picks made for IMNM stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in IMNM

Corporate Flights

Flights by private jets registered to IMNM